Piper Sandler Starts Quest Diagnostics (DGX) at Neutral

Piper Sandler analyst David Westenberg initiates coverage on Quest Diagnostics (NYSE: DGX) with a Neutral rating and a price target of $145.00.

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $141.92 yesterday.

You May Also Be Interested In

• Quest Diagnostics (DGX) Declares $0.86 Quarterly Dividend; 1.4% Yield
• Canaccord Starts Kazia Therapeutics (KZIA) at Buy
• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform